Strengths
CDI Labs possesses a unique flagship product, the HuProt™ microarray, which offers the most comprehensive collection of over 21,000 full-length human proteins, setting it apart in the proteomics market.
The company has established strong partnerships with leading research institutions, enhancing its credibility and expanding its customer base across North America, Europe, and Asia Pacific.
CDI Labs utilizes cutting-edge technology, such as advanced PhIP-Seq platforms, for accurate and comprehensive antibody profiling, which is critical for researchers in immunology and oncology.
The firm is recognized for its extensive expertise in proteomics and autoantibody profiling, which allows it to provide tailored research support to clients in various disease areas.
CDI Labs has a proven track record with over 270 peer-reviewed publications, demonstrating its commitment to advancing scientific research and contributing to critical studies.
The company’s professional and authoritative tone of voice fosters trust and reliability among its target audience, which includes pharmaceutical companies and academic institutions.
CDI Labs' focus on patient stratification and personalized medicine aligns with current trends in healthcare, making its services highly relevant and sought after.
The investment received from BroadOak indicates strong financial backing, which can be leveraged for further research and development, enhancing operational capabilities.